Drug Trial Radar · NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
680
Planned (sponsor's estimate)
Start
Sep 29, 2025
Primary completion
Mar 10, 2028
Study completion Mar 10, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation. Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.
Conditions
- Non-small Cell Carcinoma
- Non-Small Cell Lung Cancer Metastatic
- Non-Small Cell Lung Carcinoma
Interventions
PF-08046054Drug
Antibody Drug Conjugate Participants will receive PF-08046054, administered as an IV infusion.
Docetaxel monotherapyDrug
Participants will receive Docetaxel, administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Approximately 5 years
Locations
469 sites in 29 countries. Site status is shown where the registry gives one.
Alabama Oncology, Shelby
Alabaster, Alabama · Recruiting
Alabama Oncology, Bessemer
Bessemer, Alabama · Recruiting
Alabama Oncology, St Vincent's Birmingham
Birmingham, Alabama · Recruiting
Alabama Oncology, Brookwood
Birmingham, Alabama · Recruiting
Alabama Oncology, Princeton
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Alabama Oncology, St Vincent's East
Birmingham, Alabama · Recruiting
Alabama Oncology, Grandview Cancer Center
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham, IDS Pharmacy
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Southern Cancer Center
Daphne, Alabama · Recruiting
Southern Cancer Center, PC
Foley, Alabama · Recruiting
Alaska Oncology and Hematology
Anchorage, Alaska · Recruiting
Highlands Oncology Group, PA
Fayetteville, Arkansas · Recruiting
St. Bernards Medical Center
Jonesboro, Arkansas · Not yet recruiting
St. Bernards Medical Center - Paragould
Paragould, Arkansas · Not yet recruiting
Highlands Oncology Group, PA
Rogers, Arkansas · Recruiting
Highlands Oncology Group, PA
Springdale, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
UCLA Hematology/Oncology - Alhambra
Alhambra, California · Recruiting
UCLA Hematology/Oncology - Atascadero
Atascadero, California · Recruiting
Alta Bates Summit Medical Center Comprehensive Cancer Center
Berkeley, California · Recruiting
UCLA Hematology/Oncology - Burbank
Burbank, California · Recruiting
John Muir Health Clinical Research Center
Concord, California · Recruiting
UC San Diego Medical Center - Encinitas
Encinitas, California · Recruiting
UCLA Hematology/Oncoclogy-Encino
Encino, California · Recruiting
Providence Medical Foundation
Fullerton, California · Recruiting
Providence St. Jude Medical Center
Fullerton, California · Recruiting
UCLA Hematology/Oncology - Irvine
Irvine, California · Recruiting
UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Pavilion
La Jolla, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
UCSD Koman Family Outpatient Pavilion
La Jolla, California · Recruiting
UCLA Hematology/Oncology - Laguna Hills
Laguna Hills, California · Recruiting
Ronald Reagan UCLA Medical Center, Drug Information Center, Department of Pharmaceutical Services
Los Angeles, California · Recruiting
UCLA Hematology/Oncology - Marina del Rey
Marina del Rey, California · Recruiting
Providence Medical Foundation
Orange, California · Not yet recruiting
The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange
Orange, California · Not yet recruiting
UCLA Hematology/Oncology - Pasadena
Pasadena, California · Recruiting
UCLA Hematology/Oncology - Porter Ranch
Porter Ranch, California · Recruiting
Roseville Medical Plaza Care Center
Roseville, California · Recruiting
Showing 40 of 469 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.